Howell Neil J, Keogh Bruce E, Barnet Vivien, Bonser Robert S, Graham Timothy R, Rooney Stephen J, Wilson Ian C, Pagano Domenico
Department of Cardiothoracic Surgery, University Hospital NHS Foundation Trust, Birmingham, UK.
Eur J Cardiothorac Surg. 2006 Jul;30(1):10-4. doi: 10.1016/j.ejcts.2006.03.046. Epub 2006 May 24.
Patient-prosthesis mismatch (PPM) has been reported to increase perioperative mortality and reduce postoperative survival in patients undergoing aortic valve replacement (AVR). We analysed the effect of PPM at values predicting severe mismatch on survival following AVR in our unit.
Prospectively collected data on 1481 consecutive patients who had undergone AVR with or without coronary artery revascularisation between 1997 and 2005 were analysed. Projected in vitro valve effective orifice area (EOA) and geometric prosthesis internal orifice area (GOA) were evaluated and values were indexed to body surface area (cm(2)m(-2)). PPM was defined as EOAi<0.6 and/or GOAi<1.1. Long-term survival data were obtained from the National Institute of Statistics.
One thousand four hundred and eighteen patients were identified. 67/1418 (4.7%) patients had GOAi<1.1; 122/1418 (8.6%) had EOAi<0.6 and 38 (2.6%) patients exhibited both forms of mismatch. One thousand two hundred and sixty-seven patients (89%) demonstrated no mismatch (reference group). There were 75 in-hospital deaths (overall mortality 5.3%) with no significant difference between the mismatch and the reference groups. Survival data were available for up to 8 years (median 36 months, IQR 6-60 months). There were 160 late deaths (13/143 PPM group vs 147/1198 reference group). The 5-year survival estimate was similar for both groups (83% PPM group; 81% reference group; p=0.47). Cox-hazard analysis identified advanced age as the only predictor of reduced survival (age>80, RR 2.13, 95% CI 1.38-4.586, p=0.004).
Severe patient-prosthesis mismatch was predicted in 4-10% of patients undergoing AVR but this did not affect in-hospital mortality or mid-term survival.
据报道,人工瓣膜-患者不匹配(PPM)会增加主动脉瓣置换术(AVR)患者的围手术期死亡率并降低术后生存率。我们分析了在本单位中,预测为严重不匹配的PPM值对AVR术后生存的影响。
对1997年至2005年间1481例连续接受AVR手术(无论是否进行冠状动脉血运重建)患者的前瞻性收集数据进行分析。评估体外瓣膜有效瓣口面积(EOA)和人工瓣膜几何内瓣口面积(GOA)的预测值,并将其标化到体表面积(cm²m⁻²)。PPM定义为EOAi<0.6和/或GOAi<1.1。长期生存数据来自国家统计局。
共识别出1418例患者。67/1418(4.7%)例患者GOAi<1.1;122/1418(8.6%)例患者EOAi<0.6,38(2.6%)例患者同时出现两种不匹配形式。1267例患者(89%)未出现不匹配(参照组)。住院死亡75例(总死亡率5.3%),不匹配组与参照组之间无显著差异。生存数据最长随访8年(中位时间36个月,四分位间距6 - 60个月)。晚期死亡160例(PPM组13/143例,参照组147/1198例)。两组5年生存率估计相似(PPM组83%;参照组81%;p = 0.47)。Cox风险分析确定高龄是生存率降低的唯一预测因素(年龄>80岁,风险比2.13,95%置信区间1.38 - 4.586,p = 0.004)。
在接受AVR的患者中,4% - 10%被预测为严重人工瓣膜-患者不匹配,但这并不影响住院死亡率或中期生存率。